JKS logo      
Jouhou Koukai Services LLC    
 Consulting
  Overview
  Bespoke consulting
  Market Access
  Medical devices
  CTD & eCTD
  Epidemiology
  Recent Answers

 Custom publishing
  Niche Reports
  Pricing


  

  JAPAN NICHE MARKET REPORTS (JNMR)

Table- and graph-based concise report on the title product type or therapy - current status, prospects, and opportunities in Japan.

The JNMR come in two varieties: Snapshot reports - detailing the current situation of specific products or therapeutic class; and Concept report - providing overview of the market for selected conditions and relevant projections

Interferons
Snapshot report
Abstract: With the latest approval of Betaseron (recombinant beta-1b interferon) of Nihon Schering KK there are already 15 products on the market representing all types of interferon -  alpha (2a, 2b), beta, gamma, natural and recombinant, as the market is estimated to be close to 500 million US dollars annually. Advanced formulations of interferon currently under development are expected to change the market.
Hepatitis Market
Concept report
Abstract: Effective November 1, 2000 the Japanese Ministry of Health, Labor and Welfare created a special "Hepatitis Task Force". The prime objective of the joint task force is to generate policy and practical measures to counteract the growing number of HBV (1 million) and HCV (2 million) cases in Japan, and the highest in the world mortality rate of liver cancer. One of the main implications of the new policy will be the approval of new and advanced therapies still not available in Japan.
Gene and Antisense Therapy
Concept report
Abstract: Effective November 1, 2000 the Japanese Ministry of Health, Labor and Welfare created a special "Hepatitis Task Force". The prime objective of the joint task force is to generate policy and practical measures to counteract the growing number of HBV (1 million) and HCV (2 million) cases in Japan, and the highest in the world mortality rate of liver cancer. One of the main implications of the new policy will be the approval of new and advanced therapies still not available in Japan.
Pancreatic Cancer
Snapshot report
Abstract: For the past twenty years the malignant neoplasia have been the leading cause of death in Japan, and with 17,000 cases annually the pancreatic cancer is the fifth leading cause of cancer death. The classification of pancreatic tumors adopted in Japan differs from UICC system and along with comprehensive surgical approaches creates a significant market opportunities.
Quinolones Development
Concept report
Abstract: As a world leader in the field of the antibacterial therapeutics, a number of new quinolones (including fluoroquinolones) are under development by Japanese pharmaceutical companies. Opportunities for licensing and overseas marketing are reviewed.
Asthma and Allergic Rhinitis Therapies
Concept report
Abstract: Specifics of the comprehensive guidelines by the professional medical societies and the authorities (Japanese Ministry of Health, Labor and Welfare) are aligned with the size and diversity of the market for pediatric asthma therapies and the various treatments of allergic rhinitis.
Statins
Snapshot report
Abstract: Japan is the originator of one of the first and most successful statins - Mevalotin (Pravacol). Concise summaries of data on Prevalence of hyperlipidemia, classes, market and approved indications, reimbursement prices, patent expiration dates and new pipeline of lipid-controlling products.
Migraine and Headache
Concept report
Abstract: Recent simultaneous launch of two major products for treatment of migraine - Imigran (Sumatriptan succinate) Tablets 50 mg by GlaxoSmithKline KK and Zomig (Zolmitriptan) Tablets 2.5 mg by AstraZeneca KK signify the potential of the Japanese headache market. Around 8.4 milion people in Japan are estimated to suffer from migraine or other forms of headache.
Multiple Sclerosis
Concept report
Abstract: A genetical recombination of Interferon beta-1b was designated in Japan as an orphan drug for the treatment of multiple sclerosis in July 1994. The Manufacture and Import Approval for the product under the tradename Betaferon® was granted to Nihon Schering KK in September 2000. Japan is the only region where Betaferon as s.c. injections has been approved for all forms of MS, including relapsing-remitting and secondary-progressive. The development of other products such as Avonex® of Biogen is also reviewed.
Schizophrenia
Concept report
Recent changes in terminology, increased public awareness of the disease and approval of several drug for treatment of schizophrenia profoundly changed the market reflecting the evolvement of market for all major psychiatric disorders.
Insomnia
Concept report
Insomnia and its forms - similarly to all other conditions and disorders related to the mental activities, are difficult to approach and study in Japan. Cultural layers, controversies and still poorly understood patterns in the patients behavior all contribute to making the research on insomnia one of the most  complicated projects in medical and pharmaceutical market research.
Vaccines in Japan
Snapshot report
World-wide treat of newly emerging contagious diseases drew the attention of both public health regulators and vaccine developers to advanced techniques in vaccine manufacturing. Prospects of the vaccine market in Japan are evaluated and the particular regulatory requirements described.

 Update of June 2008

Copyright © 2001-2013 and Database Rights owned by Jouhou Koukai Services LLC. All rights reserved worldwide.
All materials on this web site are protected by copyrights. Jouhou Koukai and Jouhou Koukai logo are service marks of JKS LLC.

Terms & Conditions | Inquiries to Regulatory Department